News Focus
News Focus
Followers 142
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: PSea post# 196876

Sunday, 06/16/2019 5:11:33 AM

Sunday, June 16, 2019 5:11:33 AM

Post# of 447426
P-

settle down. the guy is giving you his point of view based on HIS experiences

He did not effect my mood (top of my diaphragmatic … due to LMAO).

As I said: "To avoid any doubt: I did not question your experience" and "Your experience is real" … but his view / ego is laughable.

doesn’t correspond to reality.

Medicare, hands down, has the worst coverage for Vascepa. 90 percent. Lol. In his dreams.

Do you think that the Co / CEO makes false statement about coverage? I do not see any reason to do it …

As a new drug, we are starting off with the already having pretty good managed-care coverage, considerable portion of our prescriptions currently are off label and the approval rate for managed-care is just a shade under 80%, little over 90% of adult lives on Medicare Part D covered by insurance predominantly tier 2, predominantly unrestricted, and about 80% of lives on commercial insurance covered by insurance. So, again predominantly tier 2, predominantly unrestricted.

Access

VASCEPA has unrestricted access on most plans regardless of TG level†

>80% Overall, patients have >80% unrestricted access‡
>95% Medicare Part D patients have >95% unrestricted access‡

‡As of February 8, 2019.

The Co. is working / dealing with the insurances on a daily basis … they have a detailed database (e.g. to calculate "For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program."

His approach / view just like the thinking of the Bogan who frequently refer to a Californian nurse in his posts as a proof … both are true but does not prove anything …

Best,
G

"There are some things money can't buy. For everything else, there's AMRN."

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News